Tirzepatide Therapy | Dual GIP/GLP-1

Clinical Overview

Tirzepatide uniquely activates both GIP and GLP-1 receptors. This dual mechanism has demonstrated superior weight loss outcomes in clinical trials compared to single-receptor agonists.

Clinical Safety Framing: Risk, contraindications, interactions, and follow-up planning should be reviewed before initiating any peptide pathway.

Key Benefits

Dual Receptor Activation — targets both GIP and GLP-1 pathways

Superior Efficacy — greater average weight reduction than single-mechanism therapies

Improved Lipid Profile — supports healthier cholesterol and triglycerides

Weekly Convenience — once-weekly injection with progressive titration

Frequently Asked Questions

How is it different from semaglutide?

Tirzepatide activates two receptors (GIP + GLP-1) while semaglutide activates only GLP-1, delivering broader metabolic benefits.

Clinical References & Policies

Safety Policy Medical Review Policy Evidence Methodology Sources Evidence Summary

Global Disclaimer: This content is educational and does not replace individualized medical advice. Treatment decisions should be made with a licensed clinician based on personal history, risk profile, and appropriate monitoring.

Medical Disclaimer: Information provided is for educational purposes only and does not constitute medical advice. All therapies require a consultation with a licensed clinician. Individual results may vary. Compounded medications are prepared by state-licensed 503A pharmacies and are not FDA-approved.

Ready to Get Started?

Same-day telehealth consultation with a licensed clinician.

Start Your Visit